Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease characterized by airflow limitation and is often associated with smoking. The goals of COPD are to control symptoms, reduce exacerbations, improve quality of life, and prevent disease progression.
In the 2021 edition of the Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease Disease, it is clearly pointed out that for patients who are still symptomatic after ICS+LABA or LABA+LAMA combined**, and for patients with a blood eosinophil count of 300 L and severe symptoms (CAT > 20 points), ICS+LAMA+LABA** can be considered.
First of all, we need to understand what triptych is. Triple ** refers to the simultaneous use of three drugs: a long-acting 2-receptor agonist (LABA), a long-acting anticholinergic (LAMA), and an inhaled corticosteroid (ICS).
These three drugs have different mechanisms of action, but they can work synergistically to control the symptoms of COPD more effectively.
ICS is the first-line drug that dilates the airways and relieves wheezing and wheezing.
However, many patients remain symptomatic after the initial ** stage.
In this case, it is necessary to use LABA or LAMA to enhance the effect of ICS.
These two drugs can improve airflow by blocking the contraction of the airways.
However, for some patients who are symptomatic even after the initial stage, or who have a high blood eosinophil count and are more severe in symptoms, a triple ICS+LAMA+LABA should be considered.
This can not only control symptoms more effectively, but also reduce the occurrence of exacerbations and significantly reduce the mortality rate of patients.
The implementation of triple ** needs to be carried out under the guidance of a doctor.
The doctor will decide whether to use the triple combination based on the patient's specific situation, such as the severity of the condition, age, gender, complications and other factors.
In addition, patients also need to have regular blood tests and pulmonary function tests when using triple ** to monitor the effect of the drug and possible ***
Overall, triplet is one of the important strategies of COPD.
For those who remain symptomatic after the initial stage, or who have a higher blood eosinophil count and more severe symptoms, triple can provide a more effective option.
However, each patient's condition is unique, therefore, the protocol needs to be tailored to the patient's specific situation.
Only in this way can we ensure that patients receive the best ** for them, thereby improving their quality of life, reducing the occurrence of acute exacerbations, and reducing the mortality rate.